IL17A and rheumatoid arthritis: Lastly, double blockade of IL-17A and IL-17F using Bimekizumab in RA patients with inadequate TNF-α response resulted in a greater reduction in DAS28-CRP at week 20 compared to anti-TNF-α inadequate response plus placebo group (221).